0001410578-25-001550
SEC filingRevenue surged 79% YoY in Q2 2025 to $58.4M driven by DDS segment growth, with gross margin expanding to 39%.
For the three months ended June 30, 2025, total revenue reached $58.4 million, a 79% increase from $32.6 million in the same period last year. The growth was primarily driven by the Digital Data Solutions (DDS) segment, which saw a 99% revenue surge to $50.5 million due to higher volume from an existing customer. Gross profit rose to $23.0 million from $9.3 million, with gross margin expanding to 39% from 29%, as revenue growth outpaced the 53% increase in direct operating costs. Net income swung to $7.2 million from near breakeven (a net loss of $14,000), benefiting from higher revenue and increased interest income, partially offset by higher operating expenses and a $2.3 million income tax provision (vs. $0.3 million in 2024).
The DDS segment was the primary growth engine, contributing 87% of total revenue. Its gross margin improved to 38% from 24% due to strong revenue growth. The Synodex segment posted modest 5% revenue growth to $2.1 million, with gross margin stable at 24%. Agility segment revenue increased 12% to $5.8 million, driven by higher subscriptions to its AI-enabled platform, but its gross margin remained flat at 55%. Adjusted EBITDA for the DDS segment soared to $12.2 million from $1.3 million, while Agility's adjusted EBITDA declined to $0.6 million from $1.0 million due to higher selling and administrative expenses.
Management anticipates capital expenditures of approximately $11.0 million over the next 12 months for capitalized software and infrastructure. The company believes existing cash and cash equivalents ($59.8 million at June 30, 2025) and internally generated funds will be sufficient for at least the next 12 months. No explicit revenue or earnings guidance was provided, but the focus remains on scaling the DDS segment and investing in AI capabilities. The filing of a $50 million universal shelf registration statement in October 2024 provides additional flexibility for future capital needs.
Operating cash flow (CFO) of $15.1M nearly matched consolidated net income of $15.0M, indicating high cash conversion. Non-cash charges (stock-based compensation $5.6M, depreciation and amortization $3.2M) and deferred taxes ($1.4M) were largely offset by working capital outflows, notably a $5.7M increase in accounts receivable and a $1.5M reduction in deferred revenues. Capital expenditures (capex) were $4.1M, flat year-over-year, resulting in a CFO-to-capex ratio of 3.7x. No share repurchases or dividends were reported. Financing activities provided $1.2M, driven by stock option exercises ($1.5M), partially offset by $0.2M in debt repayments. Overall, the cash flow statement shows strong operational cash generation with stable investment spending, though working capital consumption warrants monitoring.